Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ORGO Stock Alerts

Organogenesis (ORGO) Financials

Organogenesis logo
$2.36 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$2.39 +0.03 (+1.23%)
As of 07/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Organogenesis

Annual Income Statements for Organogenesis

This table shows Organogenesis' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -8.81 -65 -39 0.00 94 16 4.95 -0.94 20
Consolidated Net Income / (Loss)		 -15 -7.53 -65 -39 17 94 16 4.95 0.86 37
Net Income / (Loss) Continuing Operations		 -15 -7.53 -65 -39 17 94 16 4.95 0.86 37
Total Pre-Tax Income 		-15 -15 -65 -39 18 63 20 10 -2.81 47
Total Operating Income		 -8.78 -5.49 -52 -30 27 72 22 13 -1.28 45
Total Gross Profit		 91 137 125 185 251 353 346 327 366 427
Total Revenue		 139 199 193 261 338 467 451 433 482 564
Operating Revenue		 139 199 193 261 338 467 451 433 482 564
Total Cost of Revenue		 48 61 69 76 87 114 105 106 116 138
Operating Cost of Revenue		 48 61 69 76 87 114 105 106 116 138
Total Operating Expenses		 99 143 176 215 224 281 324 314 368 382
Selling, General & Admin Expense		 93 134 162 200 204 250 284 270 295 326
Research & Development Expense		 6.28 9.07 11 15 20 31 40 44 50 45
Other Operating Expenses / (Income)		 0.00 - 3.49 - - - 0.00 0.00 3.96 0.00
Impairment Charge		 - - - - - - 0.00 0.00 19 11
Total Other Income / (Expense), net		 -5.93 -9.06 -13 -8.71 -8.94 -9.13 -2.02 -2.13 -1.52 2.28
Interest Expense		 5.63 8.01 13 11 11 9.12 2.01 2.19 1.54 -2.28
Other Income / (Expense), net		 -0.45 -1.05 -0.31 2.15 2.34 -0.01 -0.01 0.06 0.02 -0.01
Income Tax Expense		 0.07 -7.03 0.08 0.15 0.53 -31 4.75 5.45 -3.67 9.94
Preferred Stock Dividends Declared		 - - 0.00 0.57 0.00 - 0.00 0.00 1.80 11
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - 0.42 - - - - - 0.00 0.00 5.64
Basic Earnings per Share		 ($0.27) ($0.14) ($0.94) ($0.42) $0.16 $0.73 $0.12 $0.04 ($0.01) $0.16
Weighted Average Basic Shares Outstanding		 63.20M 63.88M 69.32M 92.84M 107.74M 128.33M 130.07M 131.23M 131.67M 126.74M
Diluted Earnings per Share		 ($0.27) ($0.14) ($0.94) ($0.42) $0.15 $0.70 $0.12 $0.04 ($0.01) $0.15
Weighted Average Diluted Shares Outstanding		 63.20M 63.88M 69.32M 92.84M 111.36M 133.66M 132.38M 132.75M 131.67M 130.25M
Weighted Average Basic & Diluted Shares Outstanding		 63.20M 63.88M 69.32M 92.84M 127.99M 128.77M 131.18M 131.96M 126.83M 128.64M

Quarterly Income Statements for Organogenesis

This table shows Organogenesis' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 3.17 -0.57 -2.10 -17 12 5.88 -22 -12 15 39 -56
Consolidated Net Income / (Loss)		 3.17 -0.57 -2.10 -17 12 7.67 -19 -9.39 22 44 -53
Net Income / (Loss) Continuing Operations		 3.17 -0.57 -2.10 -17 12 7.67 -19 -9.39 22 44 -53
Total Pre-Tax Income 		7.64 -1.80 -4.34 -15 5.82 10 -26 -12 21 63 -68
Total Operating Income		 8.05 -1.27 -3.85 -14 6.24 10 -27 -13 21 63 -69
Total Gross Profit		 83 72 81 101 88 96 63 73 115 176 11
Total Revenue		 109 100 110 130 115 127 87 101 151 226 37
Operating Revenue		 109 100 110 130 115 127 87 101 151 226 37
Total Cost of Revenue		 26 28 29 29 27 31 24 28 36 50 26
Operating Cost of Revenue		 26 28 29 29 27 31 24 28 36 50 26
Total Operating Expenses		 75 73 85 115 82 85 90 86 94 112 80
Selling, General & Admin Expense		 64 61 72 77 72 74 73 74 80 100 65
Research & Development Expense		 10 12 13 16 10 12 11 10 13 10 15
Impairment Charge		 0.00 - 0.00 19 0.00 - 6.57 1.75 0.92 1.94 0.00
Total Other Income / (Expense), net		 -0.41 -0.53 -0.49 -0.65 -0.42 0.03 0.96 0.74 0.43 0.14 0.42
Interest Expense		 0.44 0.50 0.51 0.62 0.47 -0.06 -0.96 -0.67 -0.42 -0.24 -0.38
Other Income / (Expense), net		 0.03 -0.03 0.02 -0.03 0.05 -0.03 0.00 0.07 0.02 -0.10 0.04
Income Tax Expense		 4.47 -1.23 -2.24 2.50 -6.51 2.58 -6.94 -2.44 -0.41 20 -15
Preferred Stock Dividends Declared		 - - 0.00 0.00 0.00 - 2.75 2.81 2.87 2.94 3.00
Basic Earnings per Share		 $0.02 - ($0.02) ($0.13) $0.09 $0.05 ($0.17) ($0.10) $0.11 $0.32 ($0.44)
Weighted Average Basic Shares Outstanding		 131.31M 131.23M 131.86M 132.57M 132.58M 131.67M 126.30M 126.85M 126.88M 126.74M 127.80M
Diluted Earnings per Share		 $0.02 - ($0.02) ($0.13) $0.09 $0.05 ($0.17) ($0.10) $0.11 $0.31 ($0.44)
Weighted Average Diluted Shares Outstanding		 133.42M 132.75M 131.86M 132.57M 133.93M 131.67M 126.30M 126.85M 130.85M 130.25M 127.80M
Weighted Average Basic & Diluted Shares Outstanding		 132.04M 131.96M 132.57M 132.58M 132.58M 126.83M 126.85M 126.86M 126.91M 128.64M 128.67M

Annual Cash Flow Statements for Organogenesis

This table details how cash moves in and out of Organogenesis' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.66 0.50 19 39 24 30 -11 1.05 32 -42
Net Cash From Operating Activities		 -4.87 -3.49 -61 -34 5.47 62 25 31 14 -10
Net Cash From Continuing Operating Activities		 -4.87 -3.49 -61 -34 5.47 62 25 31 14 -10
Net Income / (Loss) Continuing Operations		 -15 -7.53 -65 -39 17 94 16 4.95 0.86 37
Consolidated Net Income / (Loss)		 -15 -7.53 -65 -39 17 94 16 4.95 0.86 37
Depreciation Expense		 5.70 3.59 3.31 3.78 4.44 5.78 5.85 10 14 15
Amortization Expense		 1.62 2.04 3.67 6.04 3.75 11 12 4.92 3.40 3.32
Non-Cash Adjustments To Reconcile Net Income		 12 9.79 0.67 4.72 7.49 23 16 18 42 48
Changes in Operating Assets and Liabilities, net		 -9.74 -11 -3.45 -9.37 -27 -71 -25 -7.62 -46 -114
Net Cash From Investing Activities		 -1.25 -15 -1.86 -6.23 -23 -31 -34 -24 -10 -14
Net Cash From Continuing Investing Activities		 -1.25 -15 -1.86 -6.23 -23 -31 -34 -24 -10 -14
Purchase of Property, Plant & Equipment		 -1.36 -2.43 -1.86 -5.98 -18 -31 -34 -24 -10 -14
Net Cash From Financing Activities		 6.78 19 82 79 42 -1.04 -2.20 -5.51 28 -17
Net Cash From Continuing Financing Activities		 6.78 19 82 79 42 -1.04 -2.20 -5.51 28 -17
Repayment of Debt		 -7.65 -8.60 -23 -19 -16 -65 -3.01 -5.17 -68 -1.17
Repurchase of Common Equity		 - - -0.27 -2.97 -5.66 0.00 0.00 0.00 -25 0.00
Issuance of Preferred Equity		 - - - - - - 0.00 0.00 121 0.00
Other Financing Activities, net		 17 -2.28 -11 -5.87 -0.69 0.98 0.81 -0.33 0.07 -16
Cash Interest Paid		 3.97 6.08 5.42 8.15 9.61 5.79 2.65 5.44 4.97 0.00
Cash Income Taxes Paid		 0.03 0.10 0.01 0.05 0.06 0.61 1.20 3.05 6.97 5.35

Quarterly Cash Flow Statements for Organogenesis

This table details how cash moves in and out of Organogenesis' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 9.32 5.51 -15 1.13 4.45 41 -26 -37 -9.36 30 -2.23
Net Cash From Operating Activities		 17 11 -10 4.74 8.70 11 -20 -33 3.08 39 21
Net Cash From Continuing Operating Activities		 17 11 -10 4.74 8.70 11 -20 -33 3.08 39 21
Net Income / (Loss) Continuing Operations		 3.17 -0.57 -2.10 -17 12 7.67 -19 -9.39 22 44 -53
Consolidated Net Income / (Loss)		 3.17 -0.57 -2.10 -17 12 7.67 -19 -9.39 22 44 -53
Depreciation Expense		 2.54 2.98 3.07 3.37 3.57 3.62 3.44 3.73 4.03 4.07 4.17
Amortization Expense		 1.23 1.23 0.90 0.83 0.83 0.83 0.84 0.84 0.84 0.80 5.71
Non-Cash Adjustments To Reconcile Net Income		 4.67 5.45 6.47 27 4.66 3.61 15 8.98 8.20 17 9.25
Changes in Operating Assets and Liabilities, net		 5.13 1.52 -19 -9.54 -13 -4.80 -20 -37 -32 -26 55
Net Cash From Investing Activities		 -5.98 -3.32 -2.22 -1.88 -2.57 -3.36 -3.63 -3.64 -2.24 -4.65 -3.15
Net Cash From Continuing Investing Activities		 -5.98 -3.32 -2.22 -1.88 -2.57 -3.36 -3.63 -3.64 -2.24 -4.65 -3.15
Purchase of Property, Plant & Equipment		 -5.98 -3.32 -2.22 -1.88 -2.57 -3.36 -3.63 -3.64 -2.24 -4.65 -3.15
Net Cash From Financing Activities		 -1.44 -1.78 -2.61 -1.73 -1.68 34 -2.06 -0.29 -10 -4.81 -20
Net Cash From Continuing Financing Activities		 -1.44 -1.78 -2.61 -1.73 -1.68 34 -2.06 -0.29 -10 -4.81 -20
Repayment of Debt		 -1.44 -1.78 -1.67 -1.67 -1.68 -63 -0.29 -0.29 -0.30 -0.30 -9.84
Other Financing Activities, net		 -0.00 0.00 -0.94 -0.05 0.01 1.06 -1.77 - -9.91 -4.51 -10
Cash Interest Paid		 1.29 1.54 1.38 1.37 1.36 0.87 0.00 - - - 0.00
Cash Income Taxes Paid		 -0.00 0.03 0.04 4.76 0.70 1.47 0.00 3.64 0.30 1.26 0.00

Annual Balance Sheets for Organogenesis

This table presents Organogenesis' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.42 311 149 164 221 290 443 449 460 498 599
Total Current Assets		 0.13 1.44 50 71 126 174 227 223 225 286 362
Cash & Equivalents		 0.13 1.04 2.31 21 60 84 114 102 104 136 94
Restricted Cash		 - - 0.05 0.11 0.20 0.41 0.60 0.81 0.50 0.58 0.65
Accounts Receivable		 - - 28 34 39 57 82 89 82 110 217
Inventories, net		 - - 14 13 23 28 25 25 28 26 30
Prepaid Expenses		 0.00 0.40 4.40 2.33 2.95 4.94 4.97 5.09 10 14 18
Other Current Assets		 - - 0.59 - - - - - - 0.00 2.43
Plant, Property, & Equipment, net		 0.00 0.00 42 40 47 56 79 102 116 89 104
Total Noncurrent Assets		 0.29 310 57 53 48 60 137 124 119 123 133
Goodwill		 - - 26 26 26 29 29 29 29 29 29
Intangible Assets		 - - 30 26 21 31 26 21 16 12 9.15
Noncurrent Deferred & Refundable Income Taxes		 - - 0.42 0.24 0.13 0.02 32 30 28 39 30
Other Noncurrent Operating Assets		 0.29 - 0.74 0.58 0.88 0.67 51 45 46 42 65
Total Liabilities & Shareholders' Equity		 0.42 311 149 164 221 290 443 449 460 498 599
Total Liabilities		 0.42 11 157 117 165 148 202 184 181 113 165
Total Current Liabilities		 0.42 0.48 52 56 60 68 83 75 81 77 100
Short-Term Debt		 - - 10 9.78 3.06 17 14 4.54 19 0.00 4.95
Accounts Payable		 - - 19 19 28 23 29 32 31 29 32
Accrued Expenses		 0.01 0.05 23 20 23 24 37 26 30 39 50
Other Current Liabilities		 0.41 0.43 - 6.76 5.00 4.20 1.64 12 1.08 9.11 14
Total Noncurrent Liabilities		 0.00 11 105 61 105 80 119 109 101 35 65
Capital Lease Obligations		 - - 12 15 14 14 47 0.00 27 0.72 13
Other Noncurrent Operating Liabilities		 0.00 11 8.26 5.93 7.66 13 1.56 42 13 34 52
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 295 6.76 - - - - - 0.00 122 134
Total Equity & Noncontrolling Interests		 -0.00 5.00 -15 47 56 142 241 266 279 263 300
Total Preferred & Common Equity		 -0.00 5.00 -15 47 56 142 241 266 279 263 300
Preferred Stock		 0.00 0.00 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.00 5.00 -15 47 56 142 241 266 279 263 300
Common Stock		 0.03 5.23 50 177 227 297 302 311 320 303 303
Retained Earnings		 -0.03 -0.23 -65 -130 -171 -155 -61 -45 -41 -40 -3.08

Quarterly Balance Sheets for Organogenesis

This table presents Organogenesis' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 457 446 450 463 458 443 446 467 461 510 520
Total Current Assets		 231 217 216 226 227 234 239 268 260 300 269
Cash & Equivalents		 107 89 89 98 89 90 94 110 73 64 91
Restricted Cash		 0.77 0.72 0.59 0.60 0.72 0.58 0.59 0.57 0.66 0.63 0.72
Accounts Receivable		 93 92 94 89 96 106 101 103 120 169 117
Inventories, net		 25 26 25 28 28 27 27 29 33 40 28
Prepaid Expenses		 4.71 9.85 7.95 9.57 14 11 15 18 28 23 29
Other Current Assets		 - - - - - - - 7.03 5.29 4.37 2.43
Plant, Property, & Equipment, net		 97 107 112 118 114 90 90 76 76 78 104
Total Noncurrent Assets		 130 123 122 120 117 119 118 124 125 132 147
Goodwill		 29 29 29 29 29 29 29 29 29 29 29
Intangible Assets		 22 20 18 17 15 14 13 12 11 9.94 3.44
Noncurrent Deferred & Refundable Income Taxes		 32 30 30 30 28 34 36 41 42 46 45
Other Noncurrent Operating Assets		 47 44 45 44 45 42 40 43 44 48 70
Total Liabilities & Shareholders' Equity		 457 446 450 463 458 443 446 467 461 510 520
Total Liabilities		 201 182 179 186 180 180 168 99 100 124 139
Total Current Liabilities		 89 76 73 81 83 86 77 65 66 90 76
Short-Term Debt		 17 17 18 5.48 5.49 17 16 8.07 4.80 8.58 4.76
Accounts Payable		 38 30 27 27 23 29 24 25 30 40 29
Accrued Expenses		 34 29 28 35 40 38 36 31 26 40 38
Other Current Liabilities		 0.00 0.00 0.21 14 14 1.13 1.15 1.19 4.97 1.21 4.96
Total Noncurrent Liabilities		 112 106 106 104 98 94 90 34 34 34 63
Capital Lease Obligations		 43 40 41 2.17 1.60 25 24 26 0.10 26 12
Other Noncurrent Operating Liabilities		 1.09 1.15 1.19 40 37 11 11 8.24 34 7.93 50
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - - 125 128 131 137
Total Equity & Noncontrolling Interests		 256 264 271 277 278 264 279 243 233 255 245
Total Preferred & Common Equity		 256 264 271 277 278 264 279 243 233 255 245
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 256 264 271 277 278 264 279 243 233 255 245
Common Stock		 309 313 315 317 321 324 326 302 302 302 301
Retained Earnings		 -53 -49 -44 -40 -43 -60 -48 -59 -68 -47 -56

Annual Metrics And Ratios for Organogenesis

This table displays calculated financial ratios and metrics derived from Organogenesis' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 43.09% -2.55% 34.91% 29.63% 38.15% -3.52% -3.94% 11.29% 17.04%
EBITDA Growth		 0.00% 52.20% -4,821.60% 60.18% 308.26% 138.76% -54.63% -30.69% -43.60% 301.48%
EBIT Growth		 0.00% 29.12% -693.01% 46.59% 204.84% 148.61% -69.13% -43.56% -110.04% 3,638.32%
NOPAT Growth		 0.00% 37.39% -838.41% 42.09% 223.95% 316.31% -84.16% -65.11% -115.07% 4,023.57%
Net Income Growth		 0.00% 49.04% -761.54% 40.29% 144.52% 446.61% -83.51% -68.16% -82.59% 4,201.05%
EPS Growth		 0.00% 48.15% -571.43% 55.32% 135.71% 366.67% -82.86% -66.67% -125.00% 1,600.00%
Operating Cash Flow Growth		 0.00% 28.29% -1,635.90% 44.71% 116.30% 1,033.88% -59.89% 24.37% -54.04% -172.56%
Free Cash Flow Firm Growth		 0.00% 0.00% 73.41% 9.28% 30.10% 43.44% 504.07% -196.94% 171.89% -325.23%
Invested Capital Growth		 0.00% 981.97% -6.77% 6.59% 46.60% 84.32% -9.95% 20.37% -10.96% 41.02%
Revenue Q/Q Growth		 0.00% 0.00% -41.09% 4.42% 10.51% 4.72% -2.66% -3.53% 5.93% 21.27%
EBITDA Q/Q Growth		 0.00% 0.00% 8.91% 23.93% 127.77% 1.07% -12.63% -36.05% 30.03% 541.12%
EBIT Q/Q Growth		 0.00% 0.00% -5.25% 13.96% 272.63% -2.04% -33.13% -44.11% 90.09% 637.77%
NOPAT Q/Q Growth		 0.00% 0.00% -4.63% 7.24% 1,015.95% 49.63% -73.60% -57.35% 89.95% 701.00%
Net Income Q/Q Growth		 0.00% 0.00% -5.41% 14.57% 610.33% 54.01% -73.69% -61.96% 111.67% 3,584.78%
EPS Q/Q Growth		 0.00% 0.00% -46.88% 16.00% 475.00% 45.83% -73.33% -60.00% 83.33% 236.36%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -31.16% 24.71% 122.63% -7.83% -28.99% 10.01% 2.33% 73.42%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 79.55% 58.80% -123.19% 202.81% -198.38% 173.23% 18.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 785.42% 0.34% -1.99% 52.60% -15.54% 13.25% -10.64% -0.96%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 65.26% 69.16% 64.43% 70.90% 74.19% 75.57% 76.71% 75.42% 75.99% 75.62%
EBITDA Margin		 -1.38% -0.46% -23.20% -6.85% 11.00% 19.02% 8.94% 6.45% 3.27% 11.22%
Operating Margin		 -6.33% -2.77% -26.65% -11.44% 7.89% 15.45% 4.95% 2.89% -0.27% 7.92%
EBIT Margin		 -6.65% -3.29% -26.81% -10.61% 8.59% 15.45% 4.94% 2.90% -0.26% 7.92%
Profit (Net Income) Margin		 -10.64% -3.79% -33.51% -14.83% 5.09% 20.16% 3.44% 1.14% 0.18% 6.56%
Tax Burden Percent		 100.44% 51.72% 100.13% 100.39% 97.02% 149.32% 76.58% 47.58% -30.67% 78.84%
Interest Burden Percent		 159.33% 222.48% 124.84% 139.20% 61.16% 87.37% 90.99% 82.59% 222.25% 105.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 2.98% -49.32% 23.42% 52.42% 0.00% 21.16%
Return on Invested Capital (ROIC)		 0.00% -9.00% -38.74% -22.51% 21.93% 54.00% 6.94% 2.32% -0.34% 11.70%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -5.43% -77.62% -65.38% -22.65% -113.97% 27.66% 8.97% -2.97% 10.05%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 3.84% -298.17% -52.93% -4.46% -4.83% -0.82% -0.50% 0.60% -2.66%
Return on Equity (ROE)		 -9.84% -5.16% -336.91% -75.44% 17.46% 49.17% 6.13% 1.82% 0.26% 9.04%
Cash Return on Invested Capital (CROIC)		 0.00% -115.33% -31.74% -28.88% -15.87% -5.31% 17.41% -16.17% 11.26% -22.33%
Operating Return on Assets (OROA)		 -5.92% -2.84% -33.20% -14.41% 11.37% 19.69% 4.99% 2.77% -0.26% 8.15%
Return on Assets (ROA)		 -9.47% -3.27% -41.51% -20.14% 6.75% 25.69% 3.48% 1.09% 0.18% 6.75%
Return on Common Equity (ROCE)		 -0.16% 0.18% -277.71% -75.44% 17.46% 49.17% 6.13% 1.82% 0.21% 6.21%
Return on Equity Simple (ROE_SIMPLE)		 -295.32% 49.13% -137.82% -69.64% 12.15% 39.03% 5.85% 1.77% 0.33% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.14 -3.85 -36 -21 26 108 17 5.96 -0.90 35
NOPAT Margin		 -4.43% -1.94% -18.66% -8.01% 7.66% 23.07% 3.79% 1.38% -0.19% 6.25%
Net Nonoperating Expense Percent (NNEP)		 -2.77% -3.57% 38.88% 42.87% 44.58% 167.97% -20.72% -6.65% 2.64% 1.65%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - 5.08% 1.55% -0.34% 11.26%
Cost of Revenue to Revenue		 34.74% 30.84% 35.57% 29.10% 25.81% 24.44% 23.29% 24.58% 24.01% 24.38%
SG&A Expenses to Revenue		 67.06% 67.36% 83.72% 76.67% 60.36% 53.53% 62.94% 62.28% 61.10% 57.83%
R&D to Revenue		 4.52% 4.57% 5.55% 5.67% 5.94% 6.58% 8.82% 10.25% 10.43% 7.90%
Operating Expenses to Revenue		 71.58% 71.93% 91.08% 82.34% 66.30% 60.11% 71.76% 72.52% 76.26% 67.70%
Earnings before Interest and Taxes (EBIT)		 -9.23 -6.54 -52 -28 29 72 22 13 -1.26 45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.91 -0.91 -45 -18 37 89 40 28 16 63
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 1.25 8.20 5.72 4.93 1.33 1.94 1.61 2.19
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 49.28 9.85 6.36 1.63 2.31 1.91 2.51
Price to Revenue (P/Rev)		 0.00 1.94 0.31 1.75 2.40 2.54 0.78 1.25 0.88 1.17
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 12.62 22.67 109.21 0.00 32.83
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 7.93% 4.41% 0.92% 0.00% 3.05%
Enterprise Value to Invested Capital (EV/IC)		 0.00 5.15 1.13 5.18 5.77 4.66 1.37 1.93 1.65 2.01
Enterprise Value to Revenue (EV/Rev)		 0.00 2.50 0.53 1.90 2.40 2.58 0.71 1.25 0.85 1.26
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 21.77 13.57 7.93 19.39 26.09 11.21
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 27.90 16.71 14.34 43.08 0.00 15.88
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 31.28 11.19 18.71 90.94 0.00 20.14
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 148.24 19.46 12.86 17.53 28.94 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 7.46 0.00 13.77 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 -12.55 1.37 1.81 0.59 0.55 0.27 0.38 0.00 0.03
Long-Term Debt to Equity		 0.00 -11.33 1.16 1.76 0.47 0.49 0.25 0.31 0.00 0.03
Financial Leverage		 -1.04 -0.71 3.84 0.81 0.20 0.04 -0.03 -0.06 -0.20 -0.26
Leverage Ratio		 1.04 1.58 8.12 3.75 2.59 1.91 1.76 1.67 1.44 1.34
Compound Leverage Factor		 1.66 3.51 10.13 5.21 1.58 1.67 1.60 1.38 3.21 1.41
Debt to Total Capital		 0.00% 108.66% 57.74% 64.41% 37.05% 35.37% 21.03% 27.62% 0.19% 2.86%
Short-Term Debt to Total Capital		 0.00% 10.50% 8.79% 1.96% 7.40% 3.87% 1.35% 4.84% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 98.16% 48.95% 62.46% 29.65% 31.51% 19.69% 22.78% 0.19% 2.86%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 98.33% 6.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31.71% 29.95%
Common Equity to Total Capital		 1.67% -15.51% 42.26% 35.59% 62.95% 64.63% 78.97% 72.38% 68.10% 67.19%
Debt to EBITDA		 0.00 -117.69 -1.43 -5.63 2.24 1.49 1.76 3.80 0.05 0.20
Net Debt to EBITDA		 0.00 -115.11 -0.95 -2.25 -0.04 0.20 -0.81 0.07 -8.59 -1.29
Long-Term Debt to EBITDA		 0.00 -106.32 -1.21 -5.46 1.79 1.32 1.64 3.14 0.05 0.20
Debt to NOPAT		 0.00 -27.91 -1.78 -4.81 3.22 1.23 4.14 17.84 -0.80 0.36
Net Debt to NOPAT		 0.00 -27.30 -1.19 -1.93 -0.05 0.16 -1.90 0.33 150.80 -2.31
Long-Term Debt to NOPAT		 0.00 -25.21 -1.51 -4.67 2.58 1.09 3.88 14.71 -0.80 0.36
Altman Z-Score		 0.00 2.02 -0.56 1.70 4.47 5.32 2.57 3.07 3.61 4.10
Noncontrolling Interest Sharing Ratio		 98.33% 103.54% 17.57% 0.00% 0.00% 0.00% 0.00% 0.00% 18.44% 31.27%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.00 0.96 1.27 2.10 2.56 2.74 2.97 2.80 3.69 3.62
Quick Ratio		 2.17 0.59 0.99 1.66 2.07 2.37 2.56 2.31 3.17 3.11
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -111 -30 -27 -19 -11 43 -42 30 -67
Operating Cash Flow to CapEx		 -390.93% -144.46% -3,266.97% -560.29% 30.92% 198.52% 73.33% 126.90% 141.63% -72.85%
Free Cash Flow to Firm to Interest Expense		 0.00 -13.88 -2.29 -2.47 -1.66 -1.16 21.33 -18.96 19.34 0.00
Operating Cash Flow to Interest Expense		 -0.87 -0.44 -4.71 -3.09 0.48 6.80 12.37 14.12 9.20 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1.09 -0.74 -4.85 -3.64 -1.08 3.37 -4.50 2.99 2.70 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.89 0.86 1.24 1.36 1.32 1.27 1.01 0.95 1.01 1.03
Accounts Receivable Turnover		 0.00 0.00 6.22 7.11 7.04 6.71 5.25 5.05 5.02 3.45
Inventory Turnover		 0.00 0.00 4.99 4.19 3.44 4.32 4.22 4.02 4.25 4.93
Fixed Asset Turnover		 0.00 0.00 4.73 6.01 6.57 6.93 4.97 3.96 4.69 5.85
Accounts Payable Turnover		 0.00 0.00 3.60 3.19 3.37 4.33 3.41 3.38 3.88 4.52
Days Sales Outstanding (DSO)		 0.00 0.00 58.68 51.35 51.88 54.38 69.58 72.24 72.64 105.88
Days Inventory Outstanding (DIO)		 0.00 0.00 73.18 87.08 106.00 84.41 86.55 90.90 85.89 74.11
Days Payable Outstanding (DPO)		 0.00 0.00 101.37 114.27 108.20 84.25 107.17 108.07 94.03 80.76
Cash Conversion Cycle (CCC)		 0.00 0.00 30.49 24.17 49.68 54.54 48.96 55.07 64.50 99.23
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -11 96 90 96 140 259 233 281 250 352
Invested Capital Turnover		 -12.69 4.64 2.08 2.81 2.86 2.34 1.83 1.69 1.82 1.87
Increase / (Decrease) in Invested Capital		 0.00 107 -6.53 5.92 45 118 -26 47 -31 102
Enterprise Value (EV)		 0.00 496 102 496 810 1,206 320 542 411 710
Market Capitalization		 0.00 384 59 456 812 1,189 352 540 424 657
Book Value per Share		 $0.13 ($0.40) $8.09 $0.59 $1.32 $1.88 $2.03 $2.11 $1.98 $2.36
Tangible Book Value per Share		 $0.13 ($1.82) ($0.79) $0.10 $0.76 $1.45 $1.65 $1.77 $1.67 $2.07
Total Capital		 300 99 111 156 225 373 336 385 386 447
Total Debt		 0.00 107 64 101 83 132 71 106 0.72 13
Total Long-Term Debt		 0.00 97 54 98 67 118 66 88 0.72 13
Net Debt		 -311 105 43 40 -1.34 18 -33 1.98 -135 -82
Capital Expenditures (CapEx)		 1.25 2.42 1.86 5.98 18 31 34 24 10 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.08 5.78 3.41 8.39 38 44 49 59 72 168
Debt-free Net Working Capital (DFNWC)		 0.96 8.14 25 69 123 159 152 163 208 262
Net Working Capital (NWC)		 0.96 -2.23 15 66 106 144 148 145 208 262
Net Nonoperating Expense (NNE)		 8.62 3.68 29 18 8.67 14 1.55 1.01 -1.76 -1.79
Net Nonoperating Obligations (NNO)		 -311 105 43 40 -1.34 18 -33 1.98 -135 -82
Total Depreciation and Amortization (D&A)		 7.32 5.63 6.98 9.83 8.18 17 18 15 17 19
Debt-free, Cash-free Net Working Capital to Revenue		 -0.06% 2.91% 1.76% 3.22% 11.23% 9.45% 10.83% 13.58% 15.00% 29.73%
Debt-free Net Working Capital to Revenue		 0.69% 4.10% 12.83% 26.35% 36.30% 33.96% 33.74% 37.67% 43.25% 46.45%
Net Working Capital to Revenue		 0.69% -1.12% 7.77% 25.18% 31.37% 30.87% 32.73% 33.37% 43.25% 46.45%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.03) ($0.48) ($0.94) ($0.44) $0.17 $0.74 $0.00 $0.04 ($0.01) $0.16
Adjusted Weighted Average Basic Shares Outstanding		 63.20M 38.75M 92.01M 105.36M 107.74M 128.33M 0.00 131.23M 131.67M 126.74M
Adjusted Diluted Earnings per Share		 ($0.03) ($0.48) ($0.94) ($0.44) $0.16 $0.71 $0.00 $0.04 ($0.01) $0.15
Adjusted Weighted Average Diluted Shares Outstanding		 63.20M 38.75M 92.01M 105.36M 111.36M 133.66M 0.00 132.75M 131.67M 130.25M
Adjusted Basic & Diluted Earnings per Share		 ($0.03) ($0.48) ($0.94) ($0.44) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 7.92M 9.33M 69.32M 92.84M 127.99M 128.77M 0.00 131.96M 126.83M 128.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.14 -3.85 -36 -21 26 51 17 8.77 12 44
Normalized NOPAT Margin		 -4.43% -1.94% -18.66% -8.01% 7.66% 10.82% 3.79% 2.02% 2.55% 7.81%
Pre Tax Income Margin		 -10.60% -7.33% -33.47% -14.77% 5.25% 13.50% 4.50% 2.40% -0.58% 8.33%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -1.64 -0.82 -4.03 -2.55 2.58 7.92 11.10 5.75 -0.82 0.00
NOPAT to Interest Expense		 -1.09 -0.48 -2.80 -1.92 2.30 11.83 8.50 2.72 -0.58 0.00
EBIT Less CapEx to Interest Expense		 -1.86 -1.12 -4.17 -3.10 1.01 4.49 -5.78 -5.38 -7.32 0.00
NOPAT Less CapEx to Interest Expense		 -1.31 -0.78 -2.95 -2.48 0.73 8.40 -8.37 -8.40 -7.08 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 -35.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -35.22% 0.00% -0.42% -7.68% 32.82% 0.00% 0.00% 0.00% 2,959.23% 0.00%

Quarterly Metrics And Ratios for Organogenesis

This table displays calculated financial ratios and metrics derived from Organogenesis' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 126,828,092.00 126,853,536.00 126,857,709.00 - 128,640,671.00
DEI Adjusted Shares Outstanding		 - - - - - - 126,828,092.00 126,853,536.00 126,857,709.00 - 128,640,671.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.17 -0.10 0.11 - -0.44
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -7.13% -13.73% 2.17% 11.01% 6.12% 27.10% -21.17% -22.44% 30.98% 78.13% -57.06%
EBITDA Growth		 165.78% -84.44% 366.67% -173.47% -9.75% 401.75% -15,695.83% 18.44% 139.45% 364.82% -162.58%
EBIT Growth		 352.97% -114.84% 3.75% -242.43% -22.11% 887.64% -598.46% 10.18% 229.60% 520.01% -157.45%
NOPAT Growth		 957.81% -111.92% 3.72% -272.30% 295.96% 960.92% -594.34% 9.47% 59.82% 470.18% -157.58%
Net Income Growth		 1,373.02% -107.60% 29.27% -420.60% 289.36% 1,448.51% -797.29% 44.89% 74.90% 469.53% -182.10%
EPS Growth		 0.00% 0.00% 0.00% -425.00% 350.00% 0.00% -750.00% 23.08% 22.22% 520.00% -158.82%
Operating Cash Flow Growth		 206.88% 36.08% -100.16% -45.20% -48.04% 3.04% -96.17% -793.82% -64.59% 260.43% 205.98%
Free Cash Flow Firm Growth		 129.77% -245.65% 212.06% 175.00% -158.95% 179.38% -242.31% -230.67% -195.59% -253.33% -14.03%
Invested Capital Growth		 -10.23% 20.37% -13.99% -10.35% 12.85% -10.96% 14.30% 7.20% 27.23% 41.02% 5.05%
Revenue Q/Q Growth		 -7.49% -8.18% 10.36% 18.42% -11.56% 9.97% -31.55% 16.51% 49.36% 49.54% -83.50%
EBITDA Q/Q Growth		 -10.40% -75.38% -98.69% -6,850.00% 210.06% 36.86% -253.39% 64.70% 423.11% 165.67% -186.65%
EBIT Q/Q Growth		 -17.31% -116.01% -195.90% -263.54% 145.22% 61.93% -362.40% 53.25% 265.92% 204.61% -208.96%
NOPAT Q/Q Growth		 -40.85% -126.61% -203.55% -260.64% 235.93% -42.14% -344.81% 52.98% 339.98% 106.41% -210.59%
Net Income Q/Q Growth		 -40.43% -117.97% -269.07% -711.57% 172.35% -37.77% -345.58% 50.16% 329.63% 102.62% -221.64%
EPS Q/Q Growth		 -50.00% 0.00% 0.00% -550.00% 169.23% -44.44% -440.00% 41.18% 210.00% 181.82% -241.94%
Operating Cash Flow Q/Q Growth		 93.55% -36.57% -195.75% 146.62% 83.52% 25.78% -282.27% -64.90% 109.37% 1,180.29% -46.41%
Free Cash Flow Firm Q/Q Growth		 208.85% -253.21% 360.11% -43.91% -185.55% 306.31% -243.76% 48.50% -93.52% -7.02% -6.91%
Invested Capital Q/Q Growth		 -18.55% 13.25% 3.23% 6.90% 2.53% -10.64% 16.71% 0.25% 21.69% -0.96% -13.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 76.24% 72.13% 73.91% 77.58% 76.73% 75.48% 72.64% 72.64% 75.97% 77.87% 30.77%
EBITDA Margin		 10.92% 2.93% 0.13% -7.46% 9.29% 11.56% -25.91% -7.85% 16.98% 30.17% -158.41%
Operating Margin		 7.42% -1.27% -3.50% -10.67% 5.42% 8.07% -30.85% -12.45% 13.74% 28.05% -185.05%
EBIT Margin		 7.45% -1.30% -3.48% -10.69% 5.46% 8.05% -30.85% -12.38% 13.75% 28.01% -184.95%
Profit (Net Income) Margin		 2.92% -0.57% -1.91% -13.09% 10.71% 6.06% -21.74% -9.30% 14.30% 19.37% -142.79%
Tax Burden Percent		 41.47% 31.66% 48.35% 117.21% 211.76% 74.84% 73.08% 79.36% 101.92% 68.90% 77.63%
Interest Burden Percent		 94.51% 138.87% 113.42% 104.45% 92.52% 100.60% 96.41% 94.65% 102.00% 100.37% 99.45%
Effective Tax Rate		 58.53% 0.00% 0.00% 0.00% -111.76% 25.16% 0.00% 0.00% -1.92% 31.10% 0.00%
Return on Invested Capital (ROIC)		 5.27% -1.50% -3.87% -11.61% 19.80% 10.97% -36.24% -13.25% 20.50% 36.21% -222.98%
ROIC Less NNEP Spread (ROIC-NNEP)		 8.94% -3.59% 7.99% -46.29% 26.15% 10.93% -36.00% -11.27% 17.47% 36.12% -216.47%
Return on Net Nonoperating Assets (RNNOA)		 -0.16% 0.20% 0.15% -3.65% -1.32% -2.20% 5.53% 1.08% -0.76% -9.57% 43.73%
Return on Equity (ROE)		 5.12% -1.30% -3.72% -15.26% 18.49% 8.77% -30.71% -12.17% 19.74% 26.64% -179.25%
Cash Return on Invested Capital (CROIC)		 16.12% -16.17% 17.54% 8.25% -15.46% 11.26% -19.54% -12.61% -25.81% -22.33% -4.39%
Operating Return on Assets (OROA)		 7.27% -1.24% -3.35% -10.73% 5.47% 8.10% -30.57% -11.76% 13.38% 28.82% -192.82%
Return on Assets (ROA)		 2.85% -0.54% -1.84% -13.13% 10.72% 6.10% -21.54% -8.83% 13.91% 19.93% -148.86%
Return on Common Equity (ROCE)		 5.12% -1.30% -3.72% -15.26% 18.49% 7.16% -24.76% -9.68% 15.85% 18.31% -116.59%
Return on Equity Simple (ROE_SIMPLE)		 4.70% 0.00% 2.09% -6.28% -2.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 3.34 -0.89 -2.70 -9.72 13 7.65 -19 -8.80 21 44 -48
NOPAT Margin		 3.08% -0.89% -2.45% -7.47% 11.48% 6.04% -21.60% -8.72% 14.00% 19.33% -129.54%
Net Nonoperating Expense Percent (NNEP)		 -3.67% 2.09% -11.86% 34.69% -6.35% 0.04% -0.24% -1.98% 3.03% 0.09% -6.52%
Return On Investment Capital (ROIC_SIMPLE)		 - -0.23% - - - 2.90% -6.76% -3.70% 7.30% 13.94% -18.43%
Cost of Revenue to Revenue		 23.76% 27.87% 26.09% 22.42% 23.27% 24.52% 27.36% 27.36% 24.03% 22.13% 69.23%
SG&A Expenses to Revenue		 59.17% 61.60% 65.76% 58.77% 62.33% 58.31% 83.64% 73.08% 52.86% 44.40% 175.10%
R&D to Revenue		 9.65% 11.81% 11.65% 11.97% 8.98% 9.10% 12.27% 10.29% 8.76% 4.56% 40.72%
Operating Expenses to Revenue		 68.82% 73.41% 77.41% 88.25% 71.32% 67.42% 103.49% 85.10% 62.23% 49.82% 215.82%
Earnings before Interest and Taxes (EBIT)		 8.08 -1.29 -3.83 -14 6.29 10 -27 -13 21 63 -69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 12 2.92 0.14 -9.72 11 15 -22 -7.93 26 68 -59
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.51 1.94 1.35 1.41 1.36 1.61 2.26 1.99 2.10 2.19 1.25
Price to Tangible Book Value (P/TBV)		 1.81 2.31 1.60 1.68 1.60 1.91 2.71 2.40 2.47 2.51 1.44
Price to Revenue (P/Rev)		 0.93 1.25 0.86 0.83 0.83 0.88 1.19 1.08 1.15 1.17 0.59
Price to Earnings (P/E)		 32.12 109.21 64.46 0.00 0.00 0.00 0.00 0.00 0.00 32.83 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 3.11% 0.92% 1.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.05% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.57 1.93 1.38 1.39 1.36 1.65 2.05 1.79 1.79 2.01 1.20
Enterprise Value to Revenue (EV/Rev)		 0.87 1.25 0.81 0.85 0.84 0.85 1.30 1.22 1.37 1.26 0.71
Enterprise Value to EBITDA (EV/EBITDA)		 8.89 19.39 9.71 28.65 31.37 26.09 0.00 0.00 64.43 11.21 13.70
Enterprise Value to EBIT (EV/EBIT)		 17.26 43.08 27.64 0.00 0.00 0.00 0.00 0.00 0.00 15.88 142.13
Enterprise Value to NOPAT (EV/NOPAT)		 27.80 90.94 50.98 0.00 0.00 0.00 0.00 0.00 0.00 20.14 226.45
Enterprise Value to Operating Cash Flow (EV/OCF)		 13.82 17.53 13.62 17.35 27.39 28.94 134.53 0.00 0.00 0.00 11.92
Enterprise Value to Free Cash Flow (EV/FCFF)		 9.20 0.00 7.27 15.98 0.00 13.77 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.25 0.38 0.24 0.38 0.34 0.00 0.09 0.01 0.09 0.03 0.04
Long-Term Debt to Equity		 0.23 0.31 0.22 0.31 0.29 0.00 0.07 0.00 0.07 0.03 0.03
Financial Leverage		 -0.02 -0.06 0.02 0.08 -0.05 -0.20 -0.15 -0.10 -0.04 -0.26 -0.20
Leverage Ratio		 1.73 1.67 1.67 1.67 1.64 1.44 1.43 1.45 1.44 1.34 1.32
Compound Leverage Factor		 1.63 2.32 1.89 1.75 1.51 1.45 1.38 1.37 1.47 1.34 1.31
Debt to Total Capital		 20.13% 27.62% 19.29% 27.46% 25.63% 0.19% 8.48% 1.34% 8.14% 2.86% 4.30%
Short-Term Debt to Total Capital		 1.58% 4.84% 1.59% 4.73% 4.29% 0.00% 2.01% 1.31% 2.04% 0.00% 1.20%
Long-Term Debt to Total Capital		 18.55% 22.78% 17.70% 22.72% 21.35% 0.19% 6.47% 0.03% 6.09% 2.86% 3.10%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 31.71% 31.12% 34.96% 31.14% 29.95% 34.33%
Common Equity to Total Capital		 79.87% 72.38% 80.71% 72.54% 74.37% 68.10% 60.40% 63.71% 60.72% 67.19% 61.37%
Debt to EBITDA		 1.60 3.80 1.83 7.51 7.92 0.05 -4.99 -0.97 3.46 0.20 0.64
Net Debt to EBITDA		 -0.66 0.07 -0.63 0.70 0.09 -8.59 11.18 13.64 -3.06 -1.29 -2.80
Long-Term Debt to EBITDA		 1.47 3.14 1.68 6.21 6.60 0.05 -3.81 -0.02 2.59 0.20 0.46
Debt to NOPAT		 4.99 17.84 9.63 -12.99 -10.74 -0.80 -2.02 -0.31 -5.83 0.36 10.57
Net Debt to NOPAT		 -2.08 0.33 -3.32 -1.21 -0.12 150.80 4.52 4.30 5.15 -2.31 -46.30
Long-Term Debt to NOPAT		 4.60 14.71 8.83 -10.75 -8.94 -0.80 -1.54 -0.01 -4.37 0.36 7.63
Altman Z-Score		 2.63 2.97 2.41 2.36 2.71 3.69 4.45 3.93 4.00 4.20 2.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 18.44% 19.37% 20.49% 19.69% 31.27% 34.96%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.77 2.80 2.74 2.73 3.09 3.69 4.12 3.95 3.32 3.62 3.53
Quick Ratio		 2.30 2.31 2.23 2.28 2.53 3.17 3.28 2.94 2.57 3.11 2.74
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 32 -48 39 22 -19 38 -55 -28 -55 -59 -63
Operating Cash Flow to CapEx		 279.88% 319.31% -457.34% 252.02% 338.46% 325.41% -549.78% -903.60% 137.76% 847.38% 671.55%
Free Cash Flow to Firm to Interest Expense		 71.12 -96.19 75.48 35.10 -39.52 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 37.69 21.10 -19.77 7.64 18.46 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 24.22 14.49 -24.09 4.61 13.01 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.98 0.95 0.96 1.00 1.00 1.01 0.99 0.95 0.97 1.03 1.04
Accounts Receivable Turnover		 4.92 5.05 4.63 4.49 4.78 5.02 4.60 3.80 3.45 3.45 4.67
Inventory Turnover		 4.02 4.02 4.08 4.27 4.09 4.25 3.88 3.64 3.56 4.93 4.83
Fixed Asset Turnover		 4.19 3.96 3.94 4.44 4.39 4.69 4.84 5.19 5.54 5.85 5.73
Accounts Payable Turnover		 3.27 3.38 4.06 3.93 4.43 3.88 4.63 3.69 3.70 4.52 5.24
Days Sales Outstanding (DSO)		 74.13 72.24 78.86 81.22 76.42 72.64 79.35 96.16 105.94 105.88 78.09
Days Inventory Outstanding (DIO)		 90.69 90.90 89.48 85.55 89.16 85.89 93.97 100.15 102.46 74.11 75.53
Days Payable Outstanding (DPO)		 111.64 108.07 90.00 92.98 82.37 94.03 78.90 98.79 98.73 80.76 69.66
Cash Conversion Cycle (CCC)		 53.18 55.07 78.34 73.80 83.22 64.50 94.41 97.52 109.68 99.23 83.96
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 248 281 255 273 280 250 292 292 356 352 306
Invested Capital Turnover		 1.71 1.69 1.58 1.55 1.73 1.82 1.68 1.52 1.46 1.87 1.72
Increase / (Decrease) in Invested Capital		 -28 47 -41 -31 32 -31 36 20 76 102 15
Enterprise Value (EV)		 389 542 352 380 380 411 597 523 636 710 367
Market Capitalization		 418 540 375 371 379 424 548 464 535 657 305
Book Value per Share		 $2.11 $2.11 $2.11 $1.99 $2.10 $1.98 $1.92 $1.84 $2.01 $2.36 $1.90
Tangible Book Value per Share		 $1.76 $1.77 $1.78 $1.66 $1.78 $1.67 $1.60 $1.53 $1.71 $2.07 $1.65
Total Capital		 347 385 344 363 375 386 402 366 420 447 398
Total Debt		 70 106 66 100 96 0.72 34 4.89 34 13 17
Total Long-Term Debt		 64 88 61 83 80 0.72 26 0.10 26 13 12
Net Debt		 -29 1.98 -23 9.25 1.09 -135 -76 -69 -30 -82 -75
Capital Expenditures (CapEx)		 5.98 3.32 2.22 1.88 2.57 3.36 3.63 3.64 2.24 4.65 3.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 51 59 61 75 82 72 101 125 154 168 105
Debt-free Net Working Capital (DFNWC)		 150 163 150 166 177 208 211 199 218 262 197
Net Working Capital (NWC)		 144 145 144 148 161 208 203 194 209 262 192
Net Nonoperating Expense (NNE)		 0.17 -0.32 -0.60 7.32 0.89 -0.03 0.12 0.59 -0.44 -0.10 4.93
Net Nonoperating Obligations (NNO)		 -29 1.98 -23 9.25 1.09 -135 -76 -69 -30 -82 -75
Total Depreciation and Amortization (D&A)		 3.77 4.21 3.97 4.20 4.40 4.45 4.29 4.58 4.87 4.86 9.88
Debt-free, Cash-free Net Working Capital to Revenue		 11.30% 13.58% 13.90% 16.77% 18.10% 15.00% 21.94% 29.21% 33.03% 29.73% 20.43%
Debt-free Net Working Capital to Revenue		 33.31% 37.67% 34.41% 36.95% 38.96% 43.25% 46.03% 46.37% 46.86% 46.45% 38.32%
Net Working Capital to Revenue		 32.09% 33.37% 33.15% 33.11% 35.43% 43.25% 44.27% 45.25% 45.02% 46.45% 37.40%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.02 $0.00 ($0.02) ($0.13) $0.09 $0.05 ($0.17) ($0.10) $0.11 $0.32 ($0.44)
Adjusted Weighted Average Basic Shares Outstanding		 131.31M 131.23M 131.86M 132.57M 132.58M 131.67M 126.30M 126.85M 126.88M 126.74M 127.80M
Adjusted Diluted Earnings per Share		 $0.02 $0.00 ($0.02) ($0.13) $0.09 $0.05 ($0.17) ($0.10) $0.11 $0.31 ($0.44)
Adjusted Weighted Average Diluted Shares Outstanding		 133.42M 132.75M 131.86M 132.57M 133.93M 131.67M 126.30M 126.85M 130.85M 130.25M 127.80M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 132.04M 131.96M 132.57M 132.58M 132.58M 126.83M 126.85M 126.86M 126.91M 128.64M 128.67M
Normalized Net Operating Profit after Tax (NOPAT)		 5.64 -0.89 -2.70 3.47 4.37 7.65 -14 -7.58 15 45 -48
Normalized NOPAT Margin		 5.19% -0.89% -2.45% 2.66% 3.79% 6.04% -16.29% -7.51% 10.05% 19.92% -129.54%
Pre Tax Income Margin		 7.04% -1.80% -3.95% -11.16% 5.06% 8.10% -29.74% -11.72% 14.03% 28.11% -183.93%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 18.20 -2.57 -7.45 -22.45 13.36 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 7.52 -1.77 -5.25 -15.68 28.06 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 4.73 -9.18 -11.77 -25.48 7.91 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -5.95 -8.37 -9.57 -18.72 22.61 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 2,959.23% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Organogenesis (NASDAQ: ORGO) showed a sharp sequential rebound in Q1 2026 revenue and cash generation, but the quarter also reflected a return to heavy operating losses and a meaningful drawdown in cash. Compared with Q4 2025, the company’s top line dropped seasonally, but more importantly, Q1 2026 was much weaker than the same quarter a year ago on profitability and operating cash flow. Over the last several years, ORGO has shown periods of solid revenue growth, but its margins remain highly volatile and expense-heavy.

  • Strong balance sheet liquidity: ORGO ended Q1 2026 with $91.4 million in cash and equivalents, plus $0.7 million in restricted cash, giving it a sizeable cash cushion.
  • Quarterly revenue remains meaningful: Q1 2026 revenue was $37.2 million, showing the company is still generating a substantial recurring sales base.
  • Positive operating cash flow in Q1 2026: Despite a net loss, operating cash flow was $21.1 million, helped by non-cash adjustments and working-capital inflows.
  • Debt appears manageable near term: Short-term debt was only $4.8 million at the end of Q1 2026, which is modest relative to cash on hand.
  • Gross profit stayed positive: Q1 2026 gross profit was $11.5 million, so the core business still clears product costs.
  • Revenue is highly seasonal: Q1 2026 revenue fell sharply from Q4 2025’s $225.6 million, but that comparison is not apples-to-apples because Q4 is typically the strongest quarter for many healthcare product businesses.
  • Working capital drove cash flow: The strong Q1 2026 operating cash flow was boosted by a $55.2 million favorable change in operating assets and liabilities, which may not repeat every quarter.
  • Large noncontrolling interest remains on the balance sheet: Redeemable noncontrolling interest was $136.8 million in Q1 2026, an unusual and important item that investors should understand separately from traditional equity.
  • Share count is relatively stable: Weighted average shares outstanding were 127.8 million in Q1 2026, close to recent periods, suggesting limited dilution pressure recently.
  • Profitability deteriorated sharply year over year: Q1 2026 net loss attributable to common shareholders was $56.2 million versus a $21.6 million loss in Q1 2025, and much worse than the $39.3 million profit in Q4 2025.
  • Operating loss widened: Q1 2026 operating loss was $68.9 million, reflecting expenses that overwhelmed gross profit.
  • SG&A remains extremely high: Selling, general and administrative expense was $65.2 million in Q1 2026, far above gross profit and a major drag on earnings.
  • Cash declined in the quarter: Net change in cash and equivalents was negative $2.2 million in Q1 2026, and cash fell from $99.6 million at year-end 2025 to $91.4 million.
  • Operating cash flow weakened versus recent stronger quarters: Q1 2026 operating cash flow was positive, but it was down sharply from the stronger Q4 2025 figure of $39.4 million and less dependable than prior profitable periods.

Longer-term trend: ORGO’s revenue has generally been supported, but earnings have been uneven. In 2024 and 2025, the company swung from losses to profits and back again across quarters, while costs — especially SG&A and occasional impairment charges — frequently absorbed most of the gross profit. The overall pattern suggests a business with real sales traction, but one that still has work to do before consistent profitability becomes the norm.

Bottom line: Organogenesis is not facing an immediate liquidity crisis, but investors should watch whether revenue can stabilize and whether expenses can be brought under control. Until that happens, the stock likely remains more of a turnaround story than a clean profitability story.

07/05/26 12:37 PM ETAI Generated. May Contain Errors.

Organogenesis Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Organogenesis' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Organogenesis' net income appears to be on an upward trend, with a most recent value of $37.03 million in 2025, falling from -$14.77 million in 2016. The previous period was $861 thousand in 2024. Check out Organogenesis' forecast to explore projected trends and price targets.

Organogenesis' total operating income in 2025 was $44.69 million, based on the following breakdown:
  • Total Gross Profit: $426.65 million
  • Total Operating Expenses: $381.95 million

Over the last 9 years, Organogenesis' total revenue changed from $138.73 million in 2016 to $564.17 million in 2025, a change of 306.7%.

Organogenesis' total liabilities were at $164.81 million at the end of 2025, a 46.4% increase from 2024, and a 39,477.1% increase since 2015.

In the past 10 years, Organogenesis' cash and equivalents has ranged from $126.06 thousand in 2015 to $135.57 million in 2024, and is currently $93.68 million as of their latest financial filing in 2025.

Over the last 9 years, Organogenesis' book value per share changed from 0.13 in 2016 to 2.36 in 2025, a change of 1,727.6%.


Related Companies

Financial statements for NASDAQ:ORGO last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel